Sugi Predict

Sugi Predict / Compounds / SCHEMBL10115977

SCHEMBL10115977

SCHEMBL10115977

Cc1cc(NC(=O)N2CCC(NS(=O)(=O)C(C)C)CC2)cc2c1OCO2

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ OGA O60502 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ USP2 O75604 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ MAPT P10636 1/20 0.36
▸ CCR8 P51685 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ NPSR1 Q6W5P4 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10115633 0.86 SMN1; SMN2 (0.41) SMN1; SMN2LMNAEPHX2GAAUSP2
SCHEMBL10115976 0.85 SMN1; SMN2 (0.60) SMN1; SMN2OGALMNAEPHX2TSHR
SCHEMBL10115982 0.80 CCR8 (0.39) SMN1; SMN2OGAEPHX2GAAMAPT
SCHEMBL10115983 0.78 SMN1; SMN2 (0.60) SMN1; SMN2LMNAEPHX2GAATSHR
SCHEMBL10116050 0.77 CACNA1H (0.48) LMNAUSP2TSHRNPC1
SCHEMBL10115609 0.77 LMNA (0.37) SMN1; SMN2LMNAUSP2TSHRMAPT
SCHEMBL10116170 0.77 LMNA (0.46) SMN1; SMN2LMNAUSP2TSHRMAPT
SCHEMBL10116058 0.77 LMNA (0.38) LMNAUSP2TSHRMAPTCCR8
SCHEMBL10115847 0.76 LMNA (0.59) SMN1; SMN2LMNAEPHX2GAATSHR
SCHEMBL10116049 0.75 USP2 (0.38) SMN1; SMN2LMNAUSP2TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 — — US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 — — US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 — — US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 — — US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 — — US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 — — US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 — — US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R SMN1; SMN2 2213/4885OGA 3083/4885LMNA 1925/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R SMN1; SMN2 2197/4885OGA 3263/4885LMNA 2068/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R SMN1; SMN2 2251/4885OGA 3105/4885LMNA 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.